Table 1 Baseline demographics of included patients
From: A single-arm feasibility cohort study of rivaroxaban in antiphospholipid syndrome
Demographic | N (%) or result |
|---|---|
Female sex | 39 (47.6%) |
Average age at study entry | 53.4 years |
Previous arterial events | 5 (6%) |
≥ 2 previous thromboses | 24 (29.2%) |
On warfarin at study entry | 41 (50%) |
On rivaroxaban at study entry | 38 (46.3%) |
LA positive | 46 (56%) |
aCL positive | 30 (36.6%) |
aβ2GP1 positive | 4 (4.9%) |
Double positivity | 11 (13.4%) |
Triple positivity | 0 (0%) |
SLE | 10 (8.2%) |